Who
Jason Silvers
President & CFO
Company insider
Files Form 4 as: President & CFO, Generate Biomedicines.
In numbers
- Trades disclosed
- 10
- Buys
- 1
- Sells
- 0
- Bought
- $64K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 26 Feb 2026
- Last trade
- 2 Mar 2026
- Last filed
- 2 Mar 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Mar 2026filed 2 Mar 2026 | GENB Generate BiomedicinesBiotechnology | SEC FORM 4 Bought | $8,000500 at $16.00 | filing |
| 2 Mar 2026filed 2 Mar 2026 | GENB Generate BiomedicinesBiotechnology | SEC FORM 4 Bought | $8,000500 at $16.00 | filing |
| 2 Mar 2026filed 2 Mar 2026 | GENB Generate BiomedicinesBiotechnology | SEC FORM 4 Bought | $16K1,000 at $16.00 | filing |
| 2 Mar 2026filed 2 Mar 2026 | GENB Generate BiomedicinesBiotechnology | SEC FORM 4 Bought | $8,000500 at $16.00 | filing |
| 2 Mar 2026filed 2 Mar 2026 | GENB Generate BiomedicinesBiotechnology | SEC FORM 4 Bought | $8,000500 at $16.00 | filing |
| 2 Mar 2026filed 2 Mar 2026 | GENB Generate BiomedicinesBiotechnology | SEC FORM 4 Bought | $16K1,000 at $16.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | GENB Generate Biomedicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —295,608 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | GENB Generate Biomedicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —274,493 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | GENB Generate Biomedicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —295,608 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | GENB Generate Biomedicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —274,493 at $0.00 | filing |
News
Zealand And Generate Biomedicines Team Up To Develop AI-Designed Therapies For Metabolic DiseasesGENB · rttnews.com · 14 Oct 2026Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic DiseasesGENB · manilatimes.net · 13 Oct 2026Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) & Generate Biomedicines (NASDAQ:GENB)GENB · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Jason Silvers; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.